全源造血干细胞移植在复发性/耐药性扩散性大B细胞淋巴瘤中的救援作用

相关实验视频

Updated: Jul 13, 2025

08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

7.9K

Gi-June Min¹, Young-Woo Jeon², Tong Yoon Kim²

¹Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-gu, Seoul, Republic of Korea.

Scientific reports

|October 15, 2023

概括

同源性造血干细胞移植 (allo-HSCT) 对于复发性/耐药性扩散性大B细胞淋巴瘤仍然有效,特别是在移植前实现缓解的患者中. 结果有利于化疗敏感性疾病,即使在CAR T细胞治疗时代.

科学领域:

血液学血液学血液学
在瘤学瘤学.
免疫治疗是一种免疫疗法.

背景情况:

扩散性大B细胞淋巴瘤 (DLBCL) 在复发/耐药情况下带来了挑战.
化学抗原受体 (CAR) T细胞疗法已成为一种重要的治疗方式.
在当前的治疗环境中,全源造血干细胞移植 (allo-HSCT) 的作用需要澄清.

研究的目的:

评估阿洛-HSCT在患有复发/耐药DLBCL的患者的临床结果.
确定影响alo-HSCT后生存的预后因素.
评估allo-HSCT与CAR T细胞疗法等新疗法一起的持续相关性.

主要方法:

对52名患有复发性/耐药性DLBCL的患者进行了回顾性分析,这些患者接受了allo-HSCT.
患者的分层分为在移植前实现缓解和活跃疾病组.
评估总生存 (OS),无事件生存 (EFS),复发累积发病率 (CIR),非复发死亡率 (NRM) 和GRFS.

主要成果:

总生存率和无事件生存率分别为38.4%和30.6%,随访时间中位数为38.3个月.
在缓解前的allo-HSCT患者表现出优异的OS,EFS和GRFS,CIR较低.
从诊断到alo-HSCT之间的较短间隔与较差的生存结果相关,表明疾病进展迅速.

结论:

对于一些复发性/耐药DLBCL的患者来说,Allo-HSCT仍然是一个可行的治疗选择.
在 allo-HSCT 治疗之前实现缓解是有利结果的关键因素.
艾洛-HSCT提供了可接受的结果,特别是对于化学敏感性疾病的年轻患者,即使是CAR T细胞疗法的出现.

相关概念视频

01:22

Bone Marrow Sampling and Transplants

342

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

342

01:21

Stem Cell Therapy for Tissue Regeneration

4.1K

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

4.1K

01:01

Regulation of Hematopoietic Stem Cells

3.2K

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...